Your browser doesn't support javascript.
loading
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.
Hattinger, Claudia Maria; Salaroglio, Iris Chiara; Fantoni, Leonardo; Godel, Martina; Casotti, Chiara; Kopecka, Joanna; Scotlandi, Katia; Ibrahim, Toni; Riganti, Chiara; Serra, Massimo.
Afiliação
  • Hattinger CM; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Salaroglio IC; Department of Oncology, University of Torino, Via Santena 5/bis, 10126 Torino, Italy.
  • Fantoni L; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Godel M; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.
  • Casotti C; Department of Oncology, University of Torino, Via Santena 5/bis, 10126 Torino, Italy.
  • Kopecka J; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Scotlandi K; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.
  • Ibrahim T; Department of Oncology, University of Torino, Via Santena 5/bis, 10126 Torino, Italy.
  • Riganti C; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Serra M; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Int J Mol Sci ; 24(1)2023 Jan 02.
Article em En | MEDLINE | ID: mdl-36614241
ABSTRACT
Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved. This review is intended to give an overview on the immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments that are present in the HGOS tumor microenvironment. The principle at the basis of these strategies and the possible mechanisms that HGOS cells may use to escape these treatments are presented and discussed. Finally, a list of the currently ongoing immune-based trials in HGOS is provided, together with the results that have been obtained in recently completed clinical studies. The different strategies that are presently under investigation, which are generally aimed at abrogating the immune evasion of HGOS cells, will hopefully help to indicate new treatment protocols, leading to an improvement in the prognosis of patients with this tumor.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália